Cristina Mussini discusses the current data on interleukin inhibitors for the treatment of COVID-19 and explores why tocilizumab has been associated with beneficial outcomes in some studies but not others.
Information
- Show
- Published11 February 2021 at 11:23 UTC
- Length19 min
- RatingClean